{"name":"Immunovant Sciences GmbH","slug":"immunovant-sciences-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"IMVT-1402","genericName":"IMVT-1402","slug":"imvt-1402","indication":"Generalized myasthenia gravis (gMG)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Matching Placebo SC","genericName":"Matching Placebo SC","slug":"matching-placebo-sc","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"IMVT-1402","genericName":"IMVT-1402","slug":"imvt-1402","phase":"phase_3","mechanism":"IMVT-1402 is a neonatal Fc receptor (FcRn) antagonist that reduces circulating immunoglobulin levels by blocking FcRn-mediated recycling of IgG antibodies.","indications":["Generalized myasthenia gravis (gMG)","Thyroid eye disease (TED)"],"catalyst":""},{"name":"Matching Placebo SC","genericName":"Matching Placebo SC","slug":"matching-placebo-sc","phase":"phase_3","mechanism":"This is a placebo control formulation used in clinical trials to match the subcutaneous administration route of an active investigational drug.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxONjRKcDdKQmhDRm8tcTRtQ284UVRwZ0xHMDBLVktfc04wQnlDV1FVdERUM0ZOdHpZRkdDUDVrbDFtWHRaY3drUjh4LXJ5SmNiUWcxN29Vd1ZZcU1KemxZTFZCbHVmTzdCd3dRT3Fyd3kxanRZNFdaVTFSMm9Eclctai1fSjF1dHdBdUhjYU9VWQ?oc=5","date":"2026-02-24","type":"trial","source":"openPR.com","summary":"Graves' Disease Clinical Trials Outlook 2026: Market - openPR.com","headline":"Graves' Disease Clinical Trials Outlook 2026: Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgJBVV95cUxNM3hHVGpha2ZsMVAxemxTLUNDazl4el9ZZUhDS0QtMllhamNCLTBEb2ZubjROWXJ0bWRPSUVFLXNRMDJ3cWtKU2tsZG1tM3BxRGdrS3FkYjE3bWU2LUxCTzQ3dWxKbU9YUTJHbThNQVUwWWV3TWpuVlVuTE9idDVHZFlvdEFPNkhpeWtGR3BscFA3QzRaWnlqYldfZWM1OWMzVlRMYmFONXNfT3FyWXdPcGRLQ0twRVpPYzNlYUpKd3JSLWxJOFExc3JXNUNNeFZrOW82OFU2bUNGb2M4QWN4aUNFdmZ3elJvMzgwZHBPNU9BSFR4S0YwSGpTMmhqa0NLVURlYWFacXIxUnhVQlhNU2ljbDIwMHNZWmFOWlhsUUV5cy1QSmR0WjVFaG9lTVN4ekh5a0xKc0ZZQTY1TkhqaF9n?oc=5","date":"2026-01-14","type":"pipeline","source":"GlobeNewswire","summary":"Generalized Myasthenia Gravis Market Outlook Shows Strong - GlobeNewswire","headline":"Generalized Myasthenia Gravis Market Outlook Shows Strong","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxNTVNXR2VFdWxtSUhGd2syTlVDcHNjYVZZNnNKVEs2dTFKa3lPdEVHVzhjT29OYm1aY3VLTllNSTdzZm8xcnhzcXdxcGhGbTY2TE9EMkdYTjgxSzZvWUlWaldXb1hoMmtoR1FYTlBlR0hrWHY4Q1FyQWZFOF9QaTI2eW85WTZLT0JmTnVyYnVsZnpQVFRkTml0UlZVX09NQ29FcVlPRzJXZGFienFCTWJsNU9fUkU4UlliRkZNQU4yN0FTVm9vWGxuX0JBVzcxXzYwZTRqN01iQkRQMlk2WHJEdGJDTE4tVDJkT3pwQXU5dmJ0RFdPZVhweURib2NIMzVHZUJ1VjNreWtGNUc0Y3JxLThHSUhaUWp0MXZtbFkzSEhVVUlPS0JrOQ?oc=5","date":"2025-10-16","type":"trial","source":"GlobeNewswire","summary":"Thyroid Eye Disease Clinical Trial Pipeline Gains Momentum: - GlobeNewswire","headline":"Thyroid Eye Disease Clinical Trial Pipeline Gains Momentum:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxQaHRUMHlDaFFEanVRR3I1cFRuRFZYR3B3RW1Qdkt2cnpMTEJqQ1NnVUlDQmpQd0JsTTk3cmFmcVY2OEJSX2pXcmZUV2taODdsZGJKc2ZmMnhIYy1LekROaGpGWG5yaGpzbzNhRWx1ZTdYVllYZUpRalhZc2llSDNMbndzZm5FUlZiaDhYS2NaU05JWkFCVmE4TVhUbWw0YkdFMkxRNkxIdWg1UXYyNXVFT2s4UjFLM0ZXRFNVc0xwRUJ3X2Fzc0h2dVdYNHJ5UG55VlJRXy16Ym1UbmVkSnYzM0pGVEtxZWNIOUdwRjRRWFBsRTRN?oc=5","date":"2025-05-22","type":"regulatory","source":"PR Newswire","summary":"Johnson & Johnson's IMAAVY Gets FDA Approval, Taking on Top Players in Myasthenia Gravis Market | DelveInsight - PR Newswire","headline":"Johnson & Johnson's IMAAVY Gets FDA Approval, Taking on Top Players in Myasthenia Gravis Market | DelveInsight","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxPWk56aTJpa0ROZTkwUTlHSkVadGd6TmpTUGFXNmF2NUV1TDEzYjhZTnRqcHh3M2VFUlFsZUxyRXVwdURtdWVucnpqbzl1aEkxRWo2NlZfWW1OSlRndmhiRDVRTGFNSTk5NnNFbWxfM0RPWS14Vi0zNkRKVFN5SXpoZExKbXdNZlUwdU1JSFBYSHdmOHRxVmpwdE81LWNTZVhMWW91Y1NaQkt2VUhBa1QxMDhrdVA3UVZsVWpiazNnbU1uZm5xdmFmT1VfY0dEUUxRSl9XNzNraGJDZThNRmtwVw?oc=5","date":"2025-02-20","type":"pipeline","source":"BioSpace","summary":"Rheumatoid Arthritis Market Size to Reach US$ 34.7 Billion by 2035, Impelled by Obesity and Lifestyle Changes - BioSpace","headline":"Rheumatoid Arthritis Market Size to Reach US$ 34.7 Billion by 2035, Impelled by Obesity and Lifestyle Changes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxOZjRWa1pFTWZ4TjJuU3VTZ2VtMFNrVm9VTzJEamRhXzJwbmtjSHdKVmQ2NWtTbVlnYXZMWmRFbVZ2cXFDZEJVLWNFbDRqOTAzREZqcTZzWFdibkZBTlhyVHdKa3dvTXhhMHRNYnItUW9OWW5GUlBVYW1lUWNNRWl3ZW4zQWFURHkxOHU4S2ZMa1hRbG04TEE3ZlhrTzlTdXlSODhPcUtxalhXd1p3MUFBVEFZUEZHb3RzOEpaOENUelZZcWJuYVY5WkQ2WjNKcEhsdWRSbnZNQldpaEcyNmlGZFlRamN1U1dvWWtTVWJmOTYwa0VGaC1xOENzbWo1NlFuMmpsUGluZHRIYzdMcmxmby1SZHpGRGRMQTh1OVZB?oc=5","date":"2025-02-19","type":"pipeline","source":"GlobeNewswire","summary":"TEPEZZA Market Sales on the Rise Due to the Strong Growth - GlobeNewswire","headline":"TEPEZZA Market Sales on the Rise Due to the Strong Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxOUVVGN0pqSktYbDVqOE12LWFaV0gwY1dBaW4welk1X3FwakJsTnM2ZEZwLVZJOWl0RUFlWEVjTzZEaEpIcmJyR215U1dFaVJlaGM1cDV2eU1lNGRYaS1adUlUdjF0MjhVSUlab0IxVlg2SUdmMkVXRnV0enlPTTI0YmtVUzZvR3hseHIwLWtRejd3VXl5eXZEejZnQU02TWFCLXByT21vMTJxdGNqY2hDMWFreDFYVnVHbnVSWFVlNkxya3FaN2VIczMyMFNDSktFakNSMkRtWFZpUVRNNVh0cGt5N0ZGVEo0NU1jVjFhNzNWbHNOWENlQ3E4S0kyaDVZaWhTM3d3Z0RKdlBYLUd0dWg1ajd3a1pnU2pnc2hCSVNfREY4RXB0dVJjYUpSY3I3cWhxUDdfZw?oc=5","date":"2024-10-28","type":"trial","source":"GlobeNewswire","summary":"Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ - GlobeNewswire","headline":"Complement Inhibitors Clinical Trial Pipeline Analysis: 40+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxORTlScGVBamw1Z1hMSW5VRTJUYnk0WGh3Z0dwTVBKRUpPOVNTOFdjaFRiakZSRXI4dlM5RXUxOVMzcUJwX1RqVkQtR1Rnb2lhNFd2SGk1TmtpNk9kTXFPZE8tWlNRRXJnRUJHNjU0VXJuUzhIMEZLN1Q2VWRlVUFxdW4xd05yOTNzNm5JNEIyWGh2X2xLY1RIVW1GNEdVX0FBcVFMXzcxZ3pEWGhxTTRZTnE3WGVxdy12MFM5a1Bhb0pPU2hOT1c5Q0hCdFRTeVpoamxEdVViV0U4Wm9STGZ1NFdCZDFtTlV1N3lEOWRhb2FRZVZfOEdaRGVFTWQ5cG55N2E0?oc=5","date":"2024-08-21","type":"regulatory","source":"PR Newswire","summary":"Complement Inhibitors Market is Predicted to Exhibit Remarkable Growth During the Study Period (2020-2034) | DelveInsight - PR Newswire","headline":"Complement Inhibitors Market is Predicted to Exhibit Remarkable Growth During the Study Period (2020-2034) | DelveInsigh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxPWWFhTzRkaF9USmY2dmNMclJmLXgwa2l1UEZMZ1NfVmk1Mjc3Y1hLcVkyX3FKM2I2Q2txbnU4a2JLc3Uwa2hKUEo1R08zMWZweFROT1piU0doNTVJVlU5U1RzbzZtd2dySEtzWXVhLTVEV1VJc0xiM2tjZ1FfM09FaUhVSzlEZ2V4OTJDNlZLOVBNWWtPMG9RWWpnZFQyVy1fVmdCU3Y4Ymw5anYzSGRiVzVvWldzb0JCQl9hNHI5a2RZVlBoN1JqMEk0SVlWMjVKYUNWTGhCZE9UUVE5WWEzWkhadmxLeUJyV3lmRktBcnpVaVIzY3lBeHZEQURMdw?oc=5","date":"2024-04-16","type":"trial","source":"GlobeNewswire","summary":"FcRn Inhibitor Market is Predicted to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - GlobeNewswire","headline":"FcRn Inhibitor Market is Predicted to Grow Rapidly During the Study Period (2020–2034) | DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}